“We’re doubling down to make sure this species not only adapts in the face of extreme weather but remains a fixture of California’s natural beauty and ecosystems for generations to come,” Newsom said in a statement.
Fewer than 80,000 Central Valley fall-run chinook salmon — a mainstay of the state’s salmon fishery — returned to spawn in 2022, according to the California Department of Fish and Wildlife. It’s a decline of nearly 40 percent from the previous year, and the lowest since 2009. Last year, all salmon fishing was canceled in California and much of Oregon due to low numbers projected to return from the Pacific.
The threats to California's salmon are many — dams that block migration, diversions that drain rivers, ocean conditions and climate change. And the effects of the decline are wide-ranging: loss of fishery jobs, impacts on tribes’ food security and cultures, no local supplies for restaurants and consumers, and more.
Many of the projects and solutions outlined in Newsom’s report are already underway, or under the direction of the federal government, tribes and conservation groups. Included are the historic demolition of four aging hydroelectric dams on the Klamath River, and reintroduction of endangered Sacramento River winter-run Chinook eggs to the McCloud River upstream of Lake Shasta.
Regulatory efforts include establishing minimum flows on the fiercely contested Scott and Shasta Rivers, and the long-delayed and controversial management plan for the Bay-Delta, the heart of the state’s water supply.
Some environmental groups called the plan a ploy to burnish Newsom's image after taking other steps that jeopardized salmon: his waiver of water quality requirements in the Delta that protect salmon, his support of a controversial pact with major water suppliers, and his backing of the Delta tunnel project, which the state’s environmental assessment warned could put salmon at risk.
It’s a familiar story by now, but one that has become perhaps more confusing with time because of changing public health recommendations, new vaccine boosters and our evolving understanding of the virus.
There’s no reason to panic, state epidemiologist Dr. Erica Pan said, with population immunity at high levels.
“Over the course of the last three-and-a-half years, we’re fairly sure everybody’s been exposed or vaccinated at least once, or exposed and infected whether they knew it or not,” Pan said. “There’s thankfully a lot more immunity overall.”
The test positivity rate has been growing steadily over the past two months, increasing about 8 percentage points since July to a 12.5 percent seven-day average. That’s a higher positivity rate than last winter’s surge, although testing data has become less reliable as access decreased and testing rates plummeted. But wastewater surveillance networks confirm what the testing data suggests: COVID-19 infections are on the rise across California.
The second indicator of COVID-19’s comeback — hospitalizations — is also trending upward. The number of daily new hospital admissions increased more than 87 percent since the start of summer.
The Labor Day holiday will surely fuel more transmission and hospitalizations, but hospitals are nowhere near the brink of collapse that previous surges threatened. The uptick in cases is not having a “dramatic impact on hospitals” so far, California Hospitals Association spokeswoman Jan Emerson-Shea said.
Still, public health experts recommend people take the typical precautions to prevent a serious outbreak: vaccinate, mask and isolate.
“Some people are very terrified. Most people are not thinking about (COVID-19) at all. The right answer is somewhere in between,” said Dr. Peter Chin-Hong, an infectious disease specialist at UCSF Health. “At the minimum we have enough tools to have individual protection without having mandates.”
If you’re wondering what the latest uptick means, you’re not alone. Here are answers to common questions.
U.S. District Judge Matthew Kacsmaryk suspended the U.S. Food and Drug Administration’s approval of mifepristone more than 20 years ago, arguing that it was flawed and invalid. Kacsmaryk issued a temporary stay on his ruling for seven days to allow the Biden administration to appeal. The ruling is likely to pull the drug from pharmacy shelves unless a higher court intervenes while the case moves through the appeal process.
But just hours later, a district judge in Washington state issued a conflicting ruling in a separate case, prohibiting the FDA from taking the drug off the market. Despite the confusion caused by these dueling decisions, legal experts say even the threat of a legal gray area is likely to cause providers to stop distributing the drug.
Mifepristone is the first of a two-drug regimen that makes up the majority of abortions in the U.S., according to the Guttmacher Institute, a reproductive health research and policy center. It blocks the pregnancy hormone progesterone and is also used to manage miscarriages.
While the U.S. Supreme Court’s Dobbs decision last June rescinded federal abortion protections, it left intact states’ ability to set their own abortion laws. California legislators and Gov. Gavin Newsom jumped at the chance to make the state a beacon for progressive politics, even approving financial assistance for people in other states seeking abortions in California.
But Kacsmaryk’s ruling addresses the FDA’s authority nationally, and leaves little room for states to mitigate the fallout.
“We’re in uncharted territory,” Lisa Matsubara, an attorney for Planned Parenthood Affiliates of California and vice president of policy, told CalMatters a day after Kacsmaryk heard arguments in the case in mid-March. “It will take some time to understand how this will play out in California.”